Stockscreener 앱 받기
120.40
2.28%
-2.81
시장 영업 전:
121.99
1.59
+1.32%
Gilead Sciences Inc 주식(GILD)의 최신 뉴스
Gilead (Nasdaq: GILD) to base HIV filings on Phase 3 ARTISTRY BIC/LEN trials - Stock Titan
Gilead Sciences, Inc. $GILD Shares Sold by Texas Permanent School Fund Corp - MarketBeat
Gilead Sciences, Inc. $GILD Shares Acquired by Orion Porfolio Solutions LLC - MarketBeat
Gilead Sciences stock price target raised to $150 from $140 at Wolfe Research - Investing.com
Pitcairn Co. Grows Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Kestra Investment Management LLC Acquires 9,551 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
National Bank of Canada FI Reduces Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Farmers Trust Co. Sells 11,071 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
MASTERINVEST Kapitalanlage GmbH Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Thrivent Financial for Lutherans Sells 238,111 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Stance Capital LLC Takes Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Stock Position Trimmed by China Universal Asset Management Co. Ltd. - MarketBeat
Continental Advisors LLC Sells 9,000 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Stock Traders Buy Large Volume of Gilead Sciences Call Options (NASDAQ:GILD) - MarketBeat
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $151.00 at Morgan Stanley - MarketBeat
Treasurer of the State of North Carolina Has $85.51 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
BI Asset Management Fondsmaeglerselskab A S Acquires 140,158 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Benjamin Edwards Inc. - MarketBeat
BlueCrest Capital Management Ltd Buys Shares of 13,553 Gilead Sciences, Inc. $GILD - MarketBeat
AQR Capital Management LLC Has $272.21 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Ameriprise Financial Inc. Boosts Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead, Arcus scrap late-stage trial of cancer drug combo - 1470 & 100.3 WMBD
Gilead Sciences, Inc. $GILD Shares Purchased by Adage Capital Partners GP L.L.C. - MarketBeat
‘Au Revoir TIGIT’: Gilead, Arcus Cut Gastro Cancer Drug After Late-Stage Failure - BioSpace
GILEAD SCIENCES (GILD): Morgan Stanley Raises Price Target, Main - GuruFocus
Arcus cancels work on Gilead-partnered cancer combo after trial setback - BioPharma Dive
Arcus scraps late-stage cancer trial after weak survival data - Reuters
GILD: Gilead and Arcus End STAR-221 Study Due to Lack of Efficac - GuruFocus
Arcus, Gilead to Discontinue Phase 3 Trial of Potential Cancer Treatment -- Update - marketscreener.com
Morgan Stanley Adjusts PT on Gilead Sciences to $151 From $147, Maintains Overweight Rating - marketscreener.com
Gilead and Arcus halt late-stage study for anti-TIGIT cancer drug - Seeking Alpha
Gilead Sciences, Inc. $GILD Shares Sold by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - MarketBeat
HUB Investment Partners LLC Has $5.49 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Sei Investments Co. Raises Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
NewEdge Advisors LLC Has $11.81 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Alliancebernstein L.P. Sells 809,531 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer - Oncodaily
Ex-Dividend Reminder: Gilead Sciences, Merck and Horace Mann Educators - Nasdaq
January 2026 Options Now Available For Gilead Sciences (GILD) - Nasdaq
The Manufacturers Life Insurance Company Sells 95,568 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Who Owns Gilead Sciences? Top Shareholders and Recent Insider Trades - TIKR.com
CIBC Asset Management Inc Sells 28,874 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Wells Fargo Maintains Gilead Sciences (GILD) Overweight Recommendation - Nasdaq
GILD: Wells Fargo Raises Price Target for Gilead Sciences | GILD Stock News - GuruFocus
Cantor Fitzgerald Maintains a Buy Rating on Gilead Sciences (GILD) - Insider Monkey
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $133.00 at HSBC - MarketBeat
Wells Fargo & Company Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - MarketBeat
Why You Might Be Interested In Gilead Sciences, Inc. (NASDAQ:GILD) For Its Upcoming Dividend - simplywall.st
Wells Fargo Adjusts Price Target on Gilead Sciences to $150 From $145, Maintains Overweight Rating - marketscreener.com
HSBC Adjusts Price Target on Gilead Sciences to $133 From $110, Maintains Hold Rating - marketscreener.com
Here's What We Like About Gilead Sciences' (NASDAQ:GILD) Upcoming Dividend - Yahoo Finance
30,000 Shares in Gilead Sciences, Inc. $GILD Bought by Diadema Partners LP - MarketBeat
Dymon Asia Capital Singapore PTE. LTD. Purchases Shares of 18,000 Gilead Sciences, Inc. $GILD - MarketBeat
Ariel Investments LLC Has $40.90 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Investment Management Corp of Ontario Trims Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Lombard Odier Asset Management Switzerland SA Raises Position in Gilead Sciences, Inc. $GILD - MarketBeat
State Street Corp Sells 335,515 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Ossiam Sells 15,066 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Jump Financial LLC Takes Position in Gilead Sciences, Inc. $GILD - MarketBeat
Three Catalysts Driving Investor Attention Toward Gilead Sciences - AD HOC NEWS
Gilead Sciences, Inc. $GILD Shares Sold by Bank of Nova Scotia - MarketBeat
ASH25: CAR-T Leaders Gilead, J&J Show in Multiple Myeloma; Fulcrum Rises on Sickle Cell Data - BioSpace
WINTON GROUP Ltd Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
ASH: Gilead preps filing for anito-cel on iMMagine-1 data - Pharmaphorum
What Does the Market Think About Gilead Sciences Inc? - Benzinga
Gilead Sciences, Inc. $GILD Shares Bought by Natixis - MarketBeat
35,296 Shares in Gilead Sciences, Inc. $GILD Bought by SVB Wealth LLC - MarketBeat
Gilead moves ahead on Chess Hatch project - San Mateo Daily Journal
L2 Asset Management LLC Buys 28,592 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
0.19%
0.37%
자본화:
|
볼륨(24시간):